Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

Table 2 Tofacitinib in moderate to severe ulcerative colitis: Results from trials and real-world data

Ref.	Number of patients	Dose	Response	Adverse events
OCTAVE 1[34]	476	10 mg BID	Remission at 8 weeks: 18.2%	AEs: 60%; SAEs: 3.4%
OCTAVE 2[34]	429	10 mg BID	Remission at 8 weeks: 16.6%	AEs: 54.1%; SAEs: 4.2%
OCTAVE sustain[34,35]	397	198: 5 mg BID; 197: 10 mg BID	Remission at 52 weeks: 34.3% vs 40.6%	AEs: 72%-80%; SAEs: 5.1%-5.6%
Ollech et al[36]	30	10 mg BID	At 8 weeks clinical response and remission: 40% and 20% respectively	Not mentioned
Giri et al[37]	47	10 mg BID	After 8 weeks: 70.2% achieved clinical remission. By 24 weeks 60% patients were at remission	AEs: 21.2% (two tuberculosis, one cytomegalovirus, and one HZV)
Hoffmann et al[38]	38	10 mg BID	At 8 weeks: Steroid free remission was seen in 29% of patients	Three patients developed SAEs (pneumonia, colectomy, and colonic perforation)
Sandborn et al[23]	194	10 mg BID: 33; 15 mg BID: 49	10 mg BID: Clinical response at 8 weeks: 42% with 10 mg BID	Nasopharyngitis (six patients), post-operative abscess, anal abscess (one patients), neutropenia (three patients)

SAE: Serious adverse events; OD: Once daily; BID: Twice daily; UC: Ulcerative colitis; CD: Crohn’s disease; AEs: Adverse events; HZV: Herpes zoster virus.